Bavarian Nordic (OTCMKTS:BVNRY) Hits New 52-Week High – Time to Buy?

Bavarian Nordic (OTCMKTS:BVNRY) shares reached a new 52-week high during trading on Tuesday. The stock traded as high as $12.56 and last traded at $12.55, with a volume of 2,394 shares traded. The stock had previously closed at $12.43.

Bavarian Nordic Stock Performance

The company has a market cap of $2.99 billion, a PE ratio of 12.72 and a beta of 1.25. The firm’s 50 day moving average is $11.22 and its 200-day moving average is $10.11.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its quarterly earnings data on Friday, August 21st. The company reported $0.46 earnings per share (EPS) for the quarter. The business had revenue of $316.47 million for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.

Bavarian Nordic Company Profile

Bavarian Nordic A/S is a Denmark-based biotechnology and vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. The company supplies products to government agencies, public-health organizations, healthcare providers and private-sector customers in markets around the world.

Its best-known product is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for travelers and other infectious-disease risks, including products targeting rabies, tick-borne encephalitis, typhoid and cholera, as well as selected pediatric and adult immunization needs.

Founded in 1994 and headquartered in Copenhagen, Bavarian Nordic has expanded from a vaccine research company into an international commercial vaccine manufacturer.